Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity

Biochemical and Biophysical Research Communications

Volumn 325, Issue 3, 2004, Pages 976-982

  Kihara, Takeshi ^a   Sawada, Hideyuki ^a   Nakamizo, Tomoki ^a   Kanki, Rie ^a   Yamashita, Hirofumi ^a   Maelicke, Alfred ^b   Shimohama, Shun ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

7 nicotinic acetylcholine receptors; Amyloid; Allosterically potentiating ligand; Alzheimer's disease; Galantamine; Glutamate; Neuroprotection; Nicotine; Phosphatidylinositol 3 kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; AMYLOID BETA PROTEIN; DIZOCILPINE; GALANTAMINE; GLUTAMIC ACID; NICOTINE; NICOTINIC RECEPTOR;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; BRAIN CELL; CELL PROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING;

AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GALANTAMINE; GLUTAMIC ACID; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, NICOTINIC;

EID: 8444226296     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.10.132     Document Type: Article

References (26)

1. C.M. Clark, and J.H. Karlawish Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies Ann. Intern. Med. 138 2003 400 410
2. M.A. Raskind, E.R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology 54 2000 2261 2268
3. M.A. Raskind, and E.R. Peskind Alzheimer's disease and related disorders Med. Clin. North Am. 85 2001 803 817
4. A. Maelicke, T. Coban, A. Storch, A. Schrattenholz, E.F. Pereira, and E.X. Albuquerque Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists J. Recept. Signal Transduct. Res. 17 1997 11 28
5. A. Maelicke, and E.X. Albuquerque Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease Eur. J. Pharmacol. 393 2000 165 170
6. T. Kihara, S. Shimohama, H. Sawada, J. Kimura, T. Kume, H. Kochiyama, T. Maeda, and A. Akaike Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity Ann. Neurol. 42 1997 159 163
7. T. Kihara, S. Shimohama, M. Urushitani, H. Sawada, J. Kimura, T. Kume, T. Maeda, and A. Akaike Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity Brain Res. 792 1998 331 334
8. T. Kihara, S. Shimohama, H. Sawada, K. Honda, T. Nakamizo, H. Shibasaki, T. Kume, and A. Akaike alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity J. Biol. Chem. 276 2001 13541 13546
9. E.F. Pereira, S. Reinhardt-Maelicke, A. Schrattenholz, A. Maelicke, and E.X. Albuquerque Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons J. Pharmacol. Exp. Ther. 265 1993 1474 1491
10. A. Schrattenholz, E.F. Pereira, U. Roth, K.H. Weber, E.X. Albuquerque, and A. Maelicke Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands Mol. Pharmacol. 49 1996 1 6
11. S. Shimohama, T. Taniguchi, M. Fujiwara, and M. Kameyama Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia J. Neurochem. 46 1986 288 293
12. P.J. Whitehouse, A.M. Martino, P.G. Antuono, P.R. Lowenstein, J.T. Coyle, D.L. Price, and K.J. Kellar Nicotinic acetylcholine binding sites in Alzheimer's disease Brain Res. 371 1986 146 151
13. E.K. Perry Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology Neuroscience 64 1995 385 395
14. S. Shimohama, A. Akaike, and J. Kimura Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation Ann. N.Y. Acad. Sci. 777 1996 356 361
15. A. Akaike, Y. Tamura, T. Yokota, S. Shimohama, and J. Kimura Nicotine-induced protection of cultured cortical neurons against N-methyl-d-aspartate receptor-mediated glutamate cytotoxicity Brain Res. 644 1994 181 187
16. H. Sawada, M. Ibi, T. Kihara, M. Urushitani, A. Akaike, J. Kimura, and S. Shimohama Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress Ann. Neurol. 44 1998 110 119
17. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498
18. L. del Peso, M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 278 1997 687 689
19. E.F. Pereira, M. Alkondon, S. Reinhardt, A. Maelicke, X. Peng, J. Lindstrom, P. Whiting, and E.X. Albuquerque Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells J. Pharmacol. Exp. Ther. 270 1994 768 778
20. B.A. Yankner, L.K. Duffy, and D.A. Kirschner Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides Science 250 1990 279 282
21. W.A. Dornan, D.E. Kang, A. McCampbell, and E.E. Kang Bilateral injections of beta A(25-35) + IBO into the hippocampus disrupts acquisition of spatial learning in the rat Neuroreport 5 1993 165 168
22. K. Morimoto, K. Yoshimi, T. Tonohiro, N. Yamada, T. Oda, and I. Kaneko Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons Neuroscience 84 1998 479 487
23. A. Maelicke, M. Samochocki, R. Jostock, A. Fehrenbacher, J. Ludwig, E.X. Albuquerque, and M. Zerlin Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease Biol. Psychiatry 49 2001 279 288
24. M. Samochocki, A. Hoffle, A. Fehrenbacher, R. Jostock, J. Ludwig, C. Christner, M. Radina, M. Zerlin, C. Ullmer, E.F. Pereira, H. Lubbert, E.X. Albuquerque, and A. Maelicke Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors J. Pharmacol. Exp. Ther. 305 2003 1024 1036
25. E.F. Pereira, C. Hilmas, M.D. Santos, M. Alkondon, A. Maelicke, and E.X. Albuquerque Unconventional ligands and modulators of nicotinic receptors J. Neurobiol. 53 2002 479 500
26. C.J. Frazier, Y.D. Rollins, C.R. Breese, S. Leonard, R. Freedman, and T.V. Dunwiddie Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells J. Neurosci. 18 1998 1187 1195